OTCMKTS:SPHRY Starpharma (SPHRY) Stock Price, News & Analysis $5.71 -0.04 (-0.65%) As of 09/28/2026 03:35 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartShort Interest About Starpharma Stock (OTCMKTS:SPHRY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Starpharma alerts:Sign Up Key Stats Today's Range$5.51▼$5.7150-Day Range$4.41▼$5.8052-Week Range$1.50▼$5.82Volume1,100 shsAverage Volume1,150 shsMarket Capitalization$272.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Starpharma Holdings Limited is an Australian biotechnology company focused on developing medicines and healthcare products using its proprietary dendrimer technology. Dendrimers are highly branched molecules that can be engineered for applications including drug delivery, antiviral treatment and targeted therapies. The company’s lead product is astodrimer sodium, also known as SPL7013, which was developed as a non-antibiotic treatment for bacterial vaginosis under the VivaGel brand. Starpharma has also investigated the compound and related dendrimer technologies for antiviral applications, including products designed to help prevent or reduce viral infection. Starpharma has entered licensing and commercialization arrangements for selected products and technologies in international markets. The company is headquartered in Melbourne, Australia, and its securities trade on the Australian Securities Exchange under the symbol SPL, with American depositary shares quoted over the counter in the United States under the symbol SPHRY.AI Generated. May Contain Errors. Read More Receive SPHRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Starpharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPHRY Stock News HeadlinesStarpharma CEO speaks with Proactive at the ASX SMIDcaps ConferenceSeptember 24, 2026 | finance.yahoo.comStarpharma Holdings Ltd ADR SPHRYMay 7, 2026 | morningstar.comMSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 29 at 1:00 AM | Altimetry (Ad)Starpharma enters collaboration, license agreement with GenentechSeptember 22, 2025 | msn.comStarpharma Announces a Collaboration and License Agreement with GenentechSeptember 22, 2025 | markets.businessinsider.comSPHRY Starpharma Holdings LimitedJune 19, 2025 | seekingalpha.comChange in Substantial Holder’s Voting Power at Starpharma HoldingsJune 3, 2025 | tipranks.comPleasing Signs As A Number Of Insiders Buy Starpharma Holdings StockMay 5, 2025 | uk.finance.yahoo.comSee More Headlines SPHRY Stock Analysis - Frequently Asked Questions How have SPHRY shares performed this year? Starpharma's stock was trading at $2.4250 at the beginning of the year. Since then, SPHRY shares have increased by 135.6% and is now trading at $5.7125. How do I buy shares of Starpharma? Shares of SPHRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/29/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:SPHRY CIKN/A Webwww.starpharma.com Phone(138) 532-2700Fax61-3-9510-5955Employees45Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio3.08 Sales & Book Value Annual Sales$8.18 million Price / Sales33.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book25.97Miscellaneous Outstanding Shares47,710,000Free FloatN/AMarket Cap$272.54 million OptionableNot Optionable Beta1.28 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:SPHRY) was last updated on 9/29/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Starpharma Holdings Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Starpharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
